Avacta Share Discussion Threads

[specialist_the_proud_ nigerian] 11/8/2021 16:06

Where? Will it affect Avacta? We don't do mass testing.”
You know how the system works. You don’t need to be a rocket scientist to figure out that when mass testing may be abandoned then there will be a knock on effect for all testing.

[pwhite73] 11/8/2021 16:06

AVA6000 is a pro-drug of Doxorubicin. That's why the Phase I II and III trials are applicable. Like aspirin is a pro-drug. The delivery mechanism is the same as any other drug. preCISION is the technology used to develop AVA6000.

[tickboo] 11/8/2021 16:04

Again, from lse -Not wanting to take the spotlight off AVA6000 on its long-awaited RNS day, but the Telegraph have just published an interesting article about 'learning to live with' Covid and how vaccines aren't necessarily the silver bullet they were made out to be, regarding herd immunity.https://www.telegraph.co.uk/global-health/science-and-disease/picture-shifting-vaccines-transmission-re-shaping-learn-live/In particular:"For mass events and travel, the impact could also be profound. Already UK festivals and other mass events are switching their entry requirements to require a negative test of everyone – even where visitors have been double vaccinated.International travel schemes such as the EU Covid certificate, which allows anyone who is fully vaccinated to move freely across borders, could also be tightened, with testing once again becoming a requirement for everyone. Expect, too, most airlines and train operators to continue to require their passengers to wear masks for some time to come."Still plenty to play for testing-wise, with an accurate and easy to use product!

[specialist_the_proud_ nigerian] 11/8/2021 16:04

Avct share price will depend on what replaces the mass testing program.

[specialist_the_proud_ nigerian] 11/8/2021 16:03

Rubbish day!!! This is heading back to all time lows!

[tickboo] 11/8/2021 15:53

AVA6000 is a delivery mechanism rather than a new drug. Much higher chance of success.

[indyanna] 11/8/2021 15:44

boxer_1 filtered

[indyanna] 11/8/2021 15:44

boxer_1 filtered

[indyanna] 11/8/2021 15:43

boxer_1 filtered

[indyanna] 11/8/2021 15:43

boxer_1 filtered

[indyanna] 11/8/2021 15:43

boxer_1 filtered

[boxer_1] 11/8/2021 15:29

Alastair Smith RESIGN NOW 😡

[boxer_1] 11/8/2021 15:29

Alastair Smith RESIGN NOW 😡

[boxer_1] 11/8/2021 15:29

Alastair Smith RESIGN NOW 😡

[boxer_1] 11/8/2021 15:29

Alastair Smith RESIGN NOW 😡

[boxer_1] 11/8/2021 15:29

Alastair Smith RESIGN NOW 😡

[lostabillion] 11/8/2021 15:05

Home use approval is now just a few days away imo!

[boxer_1] 11/8/2021 15:00

TICKBOO YOU ARE VERY RUDE GUY ! SO YOU HAVE NO RESPECT FOR THE ELDERLY PEOPLE???

PWHITE MIGHT BE OLD BUT HE HAS MORE KNOWLEDGE THEN ANY OF YOU HERE!!!

[boxer_1] 11/8/2021 14:58

Alastair Smith RESIGN NOW 😡

[tickboo] 11/8/2021 14:55

You have sold so why bother hanging around like a bad smell? There is a big wide world out there. Different for PWhite who is old and in a home.

[boxer_1] 11/8/2021 14:55

TOO LATE MR AS !!!

[boxer_1] 11/8/2021 14:54

AVACTA HAS LOST THE RACE BRITISHBULLS SAYS SELL SELL SELL 🚨

[grosstonnage] 11/8/2021 14:53

Look at what successful trials will unleash. Then imagine added deals.Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer(R) reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX(R) SARS-CoV-2 Lateral Flow Rapid Antigen Test and AffiDX(R) BAMS(TM) SARS-CoV-2 Assay in partnership with Adeptrix Inc.Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta a clinical stage biopharmaceutical company, commencing a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION(TM) prodrug, in patients with locally advanced or metastatic selected solid tumours.Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX,Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION(TM) platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.